S-1/A: Invizyne Technologies Inc. Files Amendment No. 1 to Form S-1 for Initial Public Offering

Invizyne Technologies Inc. has filed an amendment to its Form S-1 registration statement for an initial public offering of 4,300,000 shares of common stock at $4.00 per share.

Summary

• Invizyne Technologies Inc., a biomanufacturing company, is planning an initial public offering (IPO).
• The company intends to offer 4,300,000 shares of its common stock at a price of $4.00 per share, aiming to raise $17,200,000 before expenses.
• The underwriter, Public Ventures, LLC, is an affiliate of both Invizyne and MDB Capital Holdings, LLC, creating a conflict of interest that is being addressed by engaging Digital Offering LLC as a qualified independent underwriter.
• Invizyne is pursuing a listing on The Nasdaq Capital Market under the ticker symbol IZTC.
• The company is currently pre-revenue and is considered an emerging growth company, allowing it to take advantage of reduced disclosure requirements.
• The company plans to use the proceeds from the IPO to expand production capabilities, increase staff, expand business development, sales, and marketing, expand the R&D and technology platform, and for working capital and other general purposes.
• The company has a license agreement with The Regents of The University of California related to cell-free synthetic biochemistry technology.

Sentiment

Score: 4

Explanation: The document presents a mix of positive and negative aspects. The company has innovative technology and government grants, but it also has a limited operating history, no revenue, and a going concern statement from its accountants. The IPO is a positive step, but there are significant risks involved.

Positives

• The company's SimplePath platform has the potential to revolutionize biomanufacturing.
• The company has received substantial US government grants, particularly from the Department of Energy (DOE) and the National Institutes of Health (NIH).
• The company has a license agreement with The Regents of The University of California related to cell-free synthetic biochemistry technology.

Negatives

• Invizyne has a limited operating history and has not generated any revenues to date.
• The company anticipates needing additional funding in the future to fully develop its business plan.
• The independent accountants to the Company have issued their report with a going concern statement.
• The company does not have any sales, marketing, manufacturing and distribution capabilities or arrangements, and will need to create these as it moves towards commercialization of its products.

Risks

• The company has a limited operating history and has not generated any revenues to date.
• The company anticipates needing additional funding in the future to fully develop its business plan.
• The independent accountants to the Company have issued their report with a going concern statement.
• The synthetic biological platform being developed by the Company may not be able to develop a pipeline of commercial products.
• The company does not have any sales, marketing, manufacturing and distribution capabilities or arrangements, and will need to create these as it moves towards commercialization of its products.
• There may be regulatory hurdles that will have to be satisfied before the bio-synthesized compounds, which are the end products of the platform, can be marketed and commercially used.
• The company is highly dependent on retaining the scientific staff and being able to hire additional scientific and related managerial staff.
• Although the company has successfully achieved the production of products in the laboratory, conditions in the laboratory setting may not be reproduced in a commercial setting.
• The company's systems rely on the need for purified enzymes and co-factors for the conversions of input feedstock into final products.
• The company's business is highly dependent on a small number of products, which are based on its principal technology.
• Collaborations of various sorts, by our partner companies, such as with respect to research, testing, manufacturing and distribution, will be important to our business.
• There is extensive competition that the company will face from legacy processes and other companies seeking to use bio-manufacturing and enzyme pathways to develop products alternative to traditional chemicals and petroleum based products.
• If the company is unable to protect the intellectual property used in its technology platform and products, others may be able to copy its innovations which may impair its ability to compete effectively in its markets.
• If the company fails to comply with its obligations in the agreements under which it licenses development or commercialization rights to products or technology from third-parties, it could lose license rights that are important to its business.
• The company will incur increased costs as a result of operating as a public company, and its board of directors will be required to devote substantial time to oversight of new compliance requirements and corporate governance practices.
• The company is an emerging growth company under the JOBS Act and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make its Common Stock less attractive to investors.
• The company is a smaller reporting company within the meaning of the Securities Act of 1933, as amended, or the Securities Act, and if it takes advantage of certain exemptions from disclosure requirements available to smaller reporting companies, this could make its securities less attractive to investors and may make it more difficult to compare its performance with other public companies.
• Certain recent initial public offerings of companies with relatively small public floats have experienced extreme volatility that was seemingly unrelated to the underlying performance of the company.
• Concentration of ownership among the company's existing executive officers, directors and significant stockholders may prevent new investors from influencing significant corporate decisions.
• The price of the company's Common Stock may have little or no relationship to the historical sales price of its capital stock in its private placement transactions to date.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its Common Stock.
• The company may allocate the net proceeds from this offering in ways that differ from the estimates discussed in the section titled Use of Proceeds and with which you may not agree, and if it does not use those proceeds effectively your investment could be harmed.
• You will experience immediate dilution in the book value per share of the Common Stock you purchase.

Future Outlook

The company intends to continue to make investments in its business to respond to business opportunities and challenges, including refining its technologies, developing new products, enhancing its operating infrastructure, and expanding its operations.

Industry Context

The company operates in the biobased industry, which is addressing the world's environmentally and socioeconomically unsustainable dependence on petroleum.

Comparison to Industry Standards

• Debut Biotech and Solugen Inc. promote the advantages of cell-free enzymatic systems over cell-based systems, but their processes appear to use simple one to two step pathways.
• Codexis, Inc. partnered with Tate&Lyle and Merck & Co., Inc. on different, highly specific projects that use multi enzyme pathways, which demonstrate that enzymatic Islatravir synthesis does illustrate the potential for complex or longer enzyme cascades but their principal mission diverges from the enzymatic manufacturing of more general chemicals.
• There are many companies that focus on enzyme engineering, such as Codexis, Inc., Allozymes Pte Ltd. (Singapore), Enzymit Ltd. (Israel and US), Zymtronix Catalytic Systems, Inc., Arzeda Corp. and Quantumzyme LLP (India).
• There are many companies operating in the biofuels space, such as Valero Energy Corporation, ADM Corporation and Cargill Company and Gevo, Inc. and Butamax Advanced Biofuels LLC that focus on ethanol technologies.

Management Changes

Related Party Transactions

• During 2023, MDB Capital Holdings, LLC provided the financial services of its chief financial officer to the Company.
• The Company also received audit services which were paid by the parent and are due to be repaid.

Stakeholder Impact

• New investors will experience immediate dilution in the book value per share of the Common Stock they purchase.
• Existing shareholders may see their ownership diluted by the issuance of new shares in the IPO.

Next Steps

• The company intends to apply to list its Common Stock on The Nasdaq Capital Market under the symbol IZTC.
• The company plans to use the proceeds from the IPO to expand production capabilities, increase staff, expand business development, sales, and marketing, expand the R&D and technology platform, and for working capital and other general purposes.

Key Dates

Keywords

IPO, initial public offering, biomanufacturing, SimplePath, cannabinoids, biofuels, enzyme, synthetic biology, IZTC, Nasdaq